Agomelatine

證據等級: L5

預測適應症: 10 個

Agomelatine: From Major Depressive Disorder to Melancholia

One-Sentence Summary

Agomelatine (Valdoxan®/Thymanax®) is an atypical antidepressant approved in Europe for major depressive disorder (MDD), acting uniquely as a melatonin MT1/MT2 receptor agonist and serotonin 5-HT2C antagonist to restore circadian rhythms. Across 10 TxGNN-predicted indications in this multi-indication evaluation, Melancholia emerges as the highest-evidence actionable target, supported by 0 registered clinical trials but 20 publications including Lancet-level network meta-analyses — representing a mechanistically coherent extension into MDD’s most circadian-disruption-prominent subtype. Two additional psychiatric spectrum indications (Neurotic Depression, L2; Dysthymic Disorder, L3) also warrant further consideration, while the remaining 7 predictions carry no supporting evidence and are rated Hold.

Quick Overview

Item	Content
Original Indication	Major Depressive Disorder (MDD)
Featured Predicted Indication	Melancholia (MDD with melancholic features)
TxGNN Prediction Score	99.88%
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Multi-Indication Note: This is a 10-indication evaluation. Three indications carry clinical significance — Melancholia (L1, Rank 4), Neurotic Depression (L2, Rank 5), and Dysthymic Disorder (L3, Rank 7). The remaining seven are rated Hold (L5) due to absence of biological plausibility or supporting evidence.

Why is This Prediction Reasonable?

Although complete MOA documentation is pending full retrieval (Data Gap DG002), pharmacological target data from this Evidence Pack confirms that Agomelatine acts as an MT1/MT2 melatonin receptor agonist (MTNR1A, MTNR1B) and a 5-HT2A/2B/2C serotonin receptor antagonist (HTR2A, HTR2B, HTR2C). This dual mechanism is unique among approved antidepressants: MT1/MT2 agonism directly resets the suprachiasmatic nucleus — the brain’s master circadian clock — while 5-HT2C antagonism disinhibits dopamine and norepinephrine release in the prefrontal cortex, enhancing mood and motivation through a non-monoamine pathway. Agomelatine was explicitly the first antidepressant developed with a mechanism of action extending beyond monoaminergic neurotransmission.

Melancholia is MDD’s most biologically severe subtype, defined by profound anhedonia, psychomotor retardation or agitation, early-morning awakening, and marked diurnal mood variation — all hallmarks of circadian system dysregulation and HPA axis dysfunction. Agomelatine’s MT1/MT2 mechanism directly addresses this pathophysiology, giving it a mechanistic advantage over SSRIs/SNRIs for this specific subtype. Critically, the European Phase 3 registration trials for Agomelatine in MDD enrolled patients with melancholic features, meaning existing RCT evidence substantially overlaps with this predicted indication.

The 5-HT2C antagonist component reinforces this rationale: 5-HT2C receptors regulate the mesolimbic dopamine system, and antagonism at this receptor improves anhedonia — the cardinal, most treatment-resistant symptom of melancholia. The convergence of circadian restoration and dopaminergic disinhibition makes Agomelatine mechanistically well-suited for melancholic depression’s core neurobiology in a way that standard antidepressants are not.

Clinical Trial Evidence

Currently no clinical trials specifically investigating Agomelatine in Melancholia are registered in ClinicalTrials.gov or ICTRP.

Literature Evidence

(Melancholia — Primary Featured Indication; 20 publications retrieved, top 10 shown)

PMID	Year	Type	Journal	Key Findings
29477251	2018	Network Meta-analysis (RCT base)	Lancet	Agomelatine ranked among the most efficacious and best-tolerated antidepressants for acute MDD across 21 drugs and 522 trials
36253442	2023	Systematic Review / Meta-analysis	Molecular Psychiatry	Agomelatine efficacy, acceptability, tolerability, and safety in MDD maintenance phase; enrichment-design RCT base
39684343	2024	Systematic Review / Meta-analysis	Int J Mol Sciences	Agomelatine efficacy and safety specifically in depressed patients with comorbid diabetes mellitus; metabolically favourable profile
41135546	2025	Systematic Review	Lancet	Cardiometabolic and physiological side-effect ranking of antidepressants including agomelatine from RCT data
33549697	2021	Systematic Review	Prog Neuropsychopharmacol Biol Psychiatry	Gastrointestinal adverse event rates with agomelatine vs. other second-generation antidepressants in MDD
40129874	2025	Narrative Review	PCN Reports	Agomelatine cited among drugs with promising anti-anhedonic effects; directly relevant to melancholia’s cardinal symptom
37424409	2023	Narrative Review	Clin Psychopharmacol Neurosci	Anhedonia as a core depressive dimension and risk factor for suicidality; agomelatine’s role in reward processing deficits
34419186	2021	Narrative Review	The Lancet Psychiatry	Circadian rhythm disruption as a causal pathophysiological pathway in depressive disorders; supports agomelatine’s MT1/MT2 rationale
24328686	2014	Narrative Review	Expert Opin Pharmacother	Comprehensive review of agomelatine as MT1/MT2 agonist + 5-HT2C antagonist; mechanism, tolerability, and neurogenesis
32568567	2020	Narrative Review	Expert Opin Drug Discov	Preclinical discovery of agomelatine; established as the first antidepressant mechanism beyond monoaminergic neurotransmission

All Predicted Indications — Decision Summary

Rank	Disease	TxGNN Score	Evidence Level	Decision
1	Benign paroxysmal torticollis of infancy	99.96%	L5	Hold
2	Agoraphobia	99.95%	L5	Hold
3	Neurotic disorder	99.90%	L5	Hold
4	Melancholia	99.88%	L1	Proceed with Guardrails
5	Neurotic depression	99.88%	L2	Proceed with Guardrails
6	Ohdo syndrome and variants	99.87%	L5	Hold
7	Dysthymic disorder	99.86%	L3	Research Question
8	Ligneous conjunctivitis	99.83%	L5	Hold
9	Blepharophimosis-intellectual disability syndrome, Ohdo type	99.82%	L5	Hold
10	Keppen-Lubinsky syndrome	99.81%	L5	Hold

Ranks 1–3 and 6–10 lack biological plausibility: the benign paroxysmal torticollis, Ohdo syndrome, and Keppen-Lubinsky predictions involve gene-level pathologies (KAT6A/6B chromatin remodelling, KCNJ6 potassium channel) with no known intersection with MT/5-HT2C pathways; ligneous conjunctivitis involves plasminogen-fibrinolysis biology entirely unrelated to Agomelatine’s mechanism. These high TxGNN scores likely reflect knowledge graph topology propagation through shared psychiatric or neurological nodes rather than genuine pharmacological signal.

India Market Information

Agomelatine is currently not marketed in India. No drug authorizations or product registrations are on record with CDSCO as of the data cutoff date (2026-04-04). The drug is approved in the European Union under the brand names Valdoxan® and Thymanax® (Servier), and in several other markets, but has not received regulatory approval in India. Any future application would require a new drug approval pathway through CDSCO.

Safety Considerations

Please refer to the package insert for safety information.

Formal safety data (package insert warnings, contraindications) has not yet been retrieved from the CDSCO/TFDA official sources (Data Gap DG001). The following pharmacological targets are documented from this Evidence Pack and are relevant to safety profiling:

Receptor	Gene	Interaction Type
MT1 (melatonin)	MTNR1A	Agonist
MT2 (melatonin)	MTNR1B	Agonist
5-HT2A (serotonin)	HTR2A	Antagonist
5-HT2B (serotonin)	HTR2B	Antagonist
5-HT2C (serotonin)	HTR2C	Antagonist

Retrieval and review of the EU SmPC (Valdoxan®) is recommended as the primary interim safety reference prior to any clinical planning.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for Melancholia — Rank 4; Hold for 7 of 10 predicted indications)

Rationale: Agomelatine’s MT1/MT2 agonist + 5-HT2C antagonist dual mechanism directly addresses the circadian dysregulation and anhedonia pathophysiology of melancholia, and Lancet-level network meta-analyses with RCT bases confirm robust antidepressant efficacy across MDD populations that include patients with melancholic features — meeting the L1 evidence threshold. The drug is not currently marketed in India, creating both a regulatory challenge and a market opportunity.

To proceed, the following is needed:

MOA documentation: Retrieve full pharmacology profile from DrugBank (DB06594) API to complete mechanistic analysis (Data Gap DG002)
Safety package: Download and parse Valdoxan® EU SmPC PDF for complete warnings, contraindications, and hepatotoxicity monitoring protocol (Data Gap DG001)
Melancholia subgroup analysis: Confirm whether existing MDD RCT data includes extractable melancholia subgroup results sufficient for regulatory-grade evidence
CDSCO regulatory pathway: Assess new drug approval requirements for Agomelatine in India, including whether a Phase 3 bridging study would be required
Neurotic Depression (Rank 5, L2): Conduct focused literature review for Agomelatine-specific evidence in this diagnostic category before upgrading decision stage
Dysthymic Disorder (Rank 7, L3): Assess feasibility of an investigator-initiated study given absence of Agomelatine-specific dysthymia RCTs; confirm whether the existing antidepressant class effect meta-analysis (PMID 21527126) is sufficient to support a protocol

This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.